SPIRIT Small Vessel Registry

NCT ID: NCT00783796

Last Updated: 2019-05-08

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: NA
• Total Enrollment: 150 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-10-31
• Study Completion Date: 2013-12-31

Brief Summary

To evaluate the safety and effectiveness of the 2.25 mm XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in improving coronary luminal diameter in subjects with ischemic heart disease due to a maximum of two de novo native coronary artery lesions in small vessels, each in a different epicardial vessel.

Conditions

Coronary Artery Disease; Atherosclerosis; Myocardial Ischemia

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

2.25mm XIENCE V®

Patients receiving the 2.25 mm XIENCE V® stent

Group Type: EXPERIMENTAL

2.25 mm XIENCE V® Everolimus Eluting Coronary Stent System

Intervention Type: DEVICE

Treatment of a maximum of two de novo native coronary artery lesions in small vessels.

Interventions

2.25 mm XIENCE V® Everolimus Eluting Coronary Stent System

Treatment of a maximum of two de novo native coronary artery lesions in small vessels.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Subject must be at least 18 years of age.

2. Subject or a legally authorized representative must provide written informed consent prior to any study related procedure.

3. Subject must have evidence of myocardial ischemia (e.g., stable or unstable angina, silent ischemia, positive functional study or a reversible change in the electrocardiogram (ECG) consistent with ischemia).

4. Subject must be an acceptable candidate for coronary artery bypass graft (CABG) surgery.

5. Subject must agree not to participate in any other clinical study for a period of one year following the index procedure.

1. One target or two (two target or one target and one non-target) de novo lesion(s), each in a different epicardial vessel.

2. If there are two target lesions or one target and one non-target lesion, both lesions must satisfy the angiographic eligibility criteria.

3. The target lesion(s) or non-target lesion must be located in a major artery or branch with a visually estimated diameter stenosis of ≥50% and < 100% with a TIMI flow of ≥1.

4. The target lesion(s) or non-target lesion must be located in a native coronary artery with a reference vessel diameter by visual estimation of: Target Lesion: ≥ 2.25 mm to < 2.5 mm for treatment by the 2.25 mm XIENCE V® EECS.

Non-target Lesion: ≥2.5 mm to ≤4.25 mm for treatment by the commercial XIENCE V® EECS.

5. The target lesion(s) or non-target lesion must be located in a native coronary artery with a lesion length by visual estimation of ≤28 mm.

Exclusion Criteria

1. Subject has had a known diagnosis of acute myocardial infarction (AMI) preceding the index procedure (CK-MB (creatine kinase myocardial-band isoenzyme) ≥2 times the upper limit of normal) and CK and CK-MB levels have not returned to within normal limits at the time of procedure.

2. The subject is currently experiencing clinical symptoms consistent with new onset AMI, such as nitrate-unresponsive prolonged chest pain with ischemic ECG changes.

3. Subject has current unstable cardiac arrhythmias associated with hemodynamic instability.

4. Subject has a known left ventricular ejection fraction (LVEF) < 30% (LVEF may be obtained at the time of the index procedure if the value is unknown and if necessary).

5. Subject has received coronary brachytherapy in any epicardial vessel.

6. Subject has received any organ transplant or is on a waiting list for any organ transplant.

7. Subject is receiving or scheduled to receive chemotherapy for malignancy within 30 days prior to or within one year after the index procedure.

8. Subject is receiving or scheduled to receive planned radiation therapy to the chest or mediastinum.

9. Subject is receiving immunosuppressant therapy or has known immunosuppressive or autoimmune disease (e.g. human immunodeficiency virus, systemic lupus erythematosus etc.).

10. Subject is receiving chronic anticoagulation therapy (e.g., heparin, coumadin).

11. Subjects who will require Low Molecular Weight Heparin (LMWH) post-procedure.

12. Subject has a known hypersensitivity or contraindication to aspirin, heparin/bivalirudin, clopidogrel/ticlopidine, everolimus, cobalt, chromium, nickel, tungsten, acrylic and fluoropolymers or contrast sensitivity that cannot be adequately pre-medicated.

13. Elective surgery is planned within 12 months after the procedure that will require discontinuing either aspirin or clopidogrel.

14. Subject has a platelet count < 100,000 cells/mm3 or > 700,000 cells/mm3, a WBC (white blood cell) of < 3,000 cells/mm3, or documented or suspected liver disease (including laboratory evidence of hepatitis).

15. Subject has known renal insufficiency (eg, serum creatinine level ≥ 2.5 mg/dL, or on dialysis).

16. Subject has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions.

17. Subject has had a cerebrovascular accident/stroke or transient ischemic neurological attack (TIA) within the past six months.

18. Subject has had a significant gastro-intestinal or significant urinary bleed within the past six months.

19. Subject has extensive peripheral vascular disease that precludes safe 6 French sheath insertion.

20. Subject has other medical illness (e.g., cancer or congestive heart failure) or known history of substance abuse (alcohol, cocaine, heroin etc.) that may cause non-compliance with the protocol, confound the data interpretation or is associated with a limited life expectancy (i.e., less than one year).

21. Subject is currently participating in another clinical study that has not yet completed its primary endpoint.

22. Pregnant or nursing subjects and those who plan pregnancy in the period up to 1 year following index procedure. Female subjects of child-bearing potential must have a negative pregnancy test done within 7 days prior to the index procedure per site standard test.

1. Target lesion(s) or non-target lesion located within an arterial or saphenous vein graft or distal to a diseased (vessel irregularity per angiogram and > 20% stenosed lesion by visual estimation) arterial or saphenous vein graft.

2. Target lesion(s) or non-target lesion involving a bifurcation with a side branch ≥2 mm in diameter and/or ostial lesion > 40% stenosed by visual estimation or side branch requiring protection guide wire, or side branch requiring dilatation.

3. Total occlusion (TIMI flow 0), prior to crossing with the wire.

4. Another lesion requiring revascularization is located in the same epicardial vessel of either the target or non-target lesion.

5. Restenotic lesion.

6. Aorto-ostial lesion (within 3 mm of the aorta junction).

7. Left main location.

8. Lesion located within 2 mm of the origin of the LAD (left anterior descending) or LCX (left coronary artery)

9. Extreme angulation (≥90°) or excessive tortuosity (≥ two 45° angles) proximal to or within the target or non-target lesion.

10. Heavy calcification proximal to or within the target or non-target lesion(s).

11. Target or non-target vessel contains thrombus as indicated in the angiographic images.

12. Target lesion(s) or non-target lesion have a high probability that a procedure other than pre-dilatation and stenting will be required at the time of index procedure for treating the target and non-target vessel(s) (e.g. atherectomy, cutting balloon).

13. Target or non-target vessel(s) have previously been treated with percutaneous intervention (e.g. balloon angioplasty, stent, cutting balloon, atherectomy) < 9 months prior to index procedure.

14. A vessel not intended to be treated with a 2.25 mm XIENCE V® EECS or commercial sizes of XIENCE V® EECS that was previously treated with any type of PCI (percutaneous coronary intervention) < 90 days prior to the index procedure.

15. Additional clinically significant lesion(s) (e.g., %DS (diameter stenosis) ≥ 50%) is present in any vessel or side branch for which PCI may be required < 90 days after the index procedure.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Abbott Medical Devices

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Marco A. Costa, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Case Western University Hospital, Cleveland, OH

Locations

Scottsdale Healthcare

Scottsdale, Arizona, United States

Arkansas Heart Hospital

Little Rock, Arkansas, United States

Washington Hospital Center

Washington D.C., District of Columbia, United States

Morton Plant Hospital

Clearwater, Florida, United States

Sacred Heart Hospital

Pensacola, Florida, United States

St. Anthony Hospital

Rockford, Illinois, United States

St. John's Hospital / Prairie Education & Research Cooperative

Springfield, Illinois, United States

Union Memorial Hospital

Baltimore, Maryland, United States

Johns Hopkins Hospital

Baltimore, Maryland, United States

St. Joseph Medical Center

Towson, Maryland, United States

Baystate Medical Center

Springfield, Massachusetts, United States

Northern Michigan Hospital

Petoskey, Michigan, United States

St. Joseph Mercy Hospital

Ypsilanti, Michigan, United States

St. Cloud Hospital

Saint Cloud, Minnesota, United States

St. Patrick Hospital

Missoula, Montana, United States

Cooper Health System

Camden, New Jersey, United States

Gotham Cardiovascular Reasearch, PC. (St. Vincent's Medical Center-closing, pts moved)

New York, New York, United States

Carolinas Medical Center

Charlotte, North Carolina, United States

Presbyterian Hospital

Charlotte, North Carolina, United States

WakeMed Hospital

Raleigh, North Carolina, United States

Forsyth Medical Center

Winston-Salem, North Carolina, United States

The Christ Hospital

Cincinnati, Ohio, United States

University Hospitals Case Medical Center

Cleveland, Ohio, United States

Riverside Methodist Hospital

Columbus, Ohio, United States

EMH Regional Medical Center

Elyria, Ohio, United States

St. Vincent Mercy Medical Center

Toledo, Ohio, United States

Hillcrest Medical Center

Tulsa, Oklahoma, United States

Geisinger Medical Center

Danville, Pennsylvania, United States

Sanford USD Medical Center

Sioux Falls, South Dakota, United States

Baptist West Hospital

Knoxville, Tennessee, United States

Northwest Texas Healthcare System

Amarillo, Texas, United States

Mother Frances Hospital

Tyler, Texas, United States

Overlake Hospital Medical Center

Bellevue, Washington, United States

St. Joseph Hospital

Bellingham, Washington, United States

Countries

United States

Other Identifiers

08-383

Identifier Type: -

Identifier Source: org_study_id